CULLINAN THERAPEUTICS, INC. Proceeds from Convertible Debt
CULLINAN THERAPEUTICS, INC. (CGEM) reported Proceeds from Convertible Debt of $2.20 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2022-11-14
- CULLINAN THERAPEUTICS, INC. proceeds from convertible debt for the quarter ending 2022-09-30 was $0.00.
- CULLINAN THERAPEUTICS, INC. proceeds from convertible debt for the quarter ending 2022-06-30 was $1.40M.
- CULLINAN THERAPEUTICS, INC. proceeds from convertible debt for the quarter ending 2022-03-31 was $800.00K.
- CULLINAN THERAPEUTICS, INC. proceeds from convertible debt for the quarter ending 2021-09-30 was $0.00.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month |
|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.40M derived: sum of 2 quarters · filed 2022-11-14 | $2.20M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $2.20M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $800.00K 10-Q · filed 2022-05-16 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |